{"entity":{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","aka":["uTRACE-101"],"tldr":"A phase 2 trial of 64Cu-DOTA-AE105 in prostate cancer, run by Curasight, now recruiting.","summary":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer is a phase 2 interventional study registered as NCT06474806 by Curasight, with 168 participants planned, started 2024-06-01 and due to reach its primary completion in 2027-01-30. Interventions recorded: 64Cu-DOTA-AE105.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06474806","url":"https://clinicaltrials.gov/study/NCT06474806"}],"tags":["pipeline","ctgov-ingest"],"related":["cu-64"],"indications":["prostate"],"sections":[],"technologies":["pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06474806","phase":"2","setting":"An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.","sponsor":"Curasight","enrolled":168,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06474806/","neighbours":{"isotope":[{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"}],"target":[{"id":"upar","kind":"target","name":"uPAR (urokinase plasminogen activator receptor)","route":"/targets/upar/"}]}}